Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects

A Single Dose Bioavailability Study of 3 New Formulations of SKI-606 (500 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects

To evaluate the comparative bioavailability of 3 new tablet formulations of SKI-606 with a reference capsule and an oral solution in healthy subjects.

Criteria:

• Healthy male and female aged 18 to 50 years.
• Women of nonchildbearing potential (WONCBP).